Program
SPN-817
A development code.
Its studies are mostly in Seizures · Epilepsy, led by Supernus Pharmaceuticals.
Furthest: phase 2, since Aug 23, 20223 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Supernus Pharmaceuticals | 33 open or running | phase 2since Aug 23, 2022 | Aug 23, 2022 | Aug 2027phase 2 · NCT06798896 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2022First study: phase 2 study in EpilepsyFirst studyNCT05518578 · 60 planned · United States, Australia
- Jan 16, 2025Phase 2 study in SeizuresNCT06798896 · 216 planned · United States, Australia, Bulgaria and more
- Aug 19, 2025Phase 2 study in SeizuresNCT07141329 · 100 planned · United States, Australia
Ahead
- Aug 2027Primary completion: phase 2 study in SeizuresNCT06798896
- Dec 31, 2027Primary completion: phase 2 study in SeizuresNCT07141329
- Dec 31, 2027Primary completion: phase 2 study in EpilepsyNCT05518578
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07141329Seizures · United States, Australia | 2 | By invitation | Dec 31, 2027 | 100 |
| NCT06798896Seizures · United States, Australia, Bulgaria and more | 2 | Recruiting | Aug 2027 | 216 |
| NCT05518578Epilepsy · United States, Australia | 2 | Recruiting | Dec 31, 2027 | 60 |
How it is read
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.